Spark et al. invest £1.5m in Cytox

Spark invested via the North West Fund for Biomedical, which it manages on behalf of the North West Fund umbrella vehicle.

New backer Seneca Partners also took part in the round alongside existing private and venture capital investors including Wren Capital and Midven, the latter of which invested via the Rainbow Seed Fund.

Previous funding
The company's first institutional funding round took place in March 2007, when Midven led a £1.25m round alongside Nesta and angel investors, according to unquote" data.

This was followed by a further capital injection of £600,000 in June 2009. Masa Life Science Investors led the round, which also saw Midven, company management and angel investor Jim Foght participate.

According to unquote" data, in May 2011 Nesta wrote off its investment in Cytox when the company went into administration.

In February last year, Midven and other new and existing investors in the company injected a further £3.5m into Cytox.

Company
Initially founded in 2006 and re-established in 2013, Manchester-headquartered Cytox is developing tests for the risk assessment and prediction of Alzheimer's disease.

The company is currently carrying out two clinical programmes, located in Europe and the US. Cytox also has a partnership with US-based laboratory Selah Genomics.

People
Richard Pither is the CEO of Cytox. Penny Attridge is a senior investment director at Spark, while Richard Manley works for Seneca.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Early-stage
• Healthcare
• Midven
• SPARK Ventures
• United Kingdom